U.S. Life Sciences Stock News

Wondering whether Intuitive Machines stock still offers value after its recent volatility, or if you might be turning up late to the story? The stock closed at US$24.11, with a 4.9% decline over the last 7 days, a 6.1% gain over 30 days, a 34.8% return year to date, and a 157.9% return over the past year. Recent headlines around Intuitive Machines have kept the stock in focus, with investors paying closer attention to how its projects translate into long term potential. This context helps...

eXp World Holdings (AGNT) recently drew attention after eXp Commercial added veteran broker Mario J Alvarez Jr, whose two decades in commercial real estate align with the company’s effort to grow its investment sales presence. See our latest analysis for eXp World Holdings. At a share price of $6.60, eXp World Holdings has a 30 day share price return of 10.18% and a 7 day gain of 2.48%. However, the year to date share price return of 27.47% and 90 day share price return of 23.79% point to...

If you are wondering whether Grindr stock is priced fairly or if the current level still leaves room for value, you need to look past headlines and into the numbers that shape valuation. Over the last month the share price has moved to US$13.81, with returns of 3.3% over 7 days, 12.4% over 30 days and 3.8% year to date, set against a 43.5% loss over the past year and a 124.2% gain over three years. Recent coverage has focused on Grindr as a listed platform business and how investors are...

If you are trying to figure out whether Apellis Pharmaceuticals is attractively priced today, it helps to start with how the current market value lines up against different ways of estimating fair value. The stock last closed at US$41.01, with returns of 0.1% over 7 days, 0.8% over 30 days, 58.6% year to date and 130.3% over the past year, alongside 3 year and 5 year returns of 53.7% decline and 10.1% decline respectively. This gives a mixed picture for anyone thinking about entry or exit...

Vistra (VST) has wrapped up FY 2025 with fourth quarter revenue of US$4.6b, Basic EPS of US$0.55 and net income of US$185m, rounding out a trailing twelve month picture that totals US$17.7b in revenue, Basic EPS of US$2.22 and net income of US$752m. Over recent quarters, reported revenue has moved from US$4.0b in Q4 2024 to US$4.6b in Q4 2025, while quarterly Basic EPS has ranged from US$1.16 in Q4 2024 to US$0.55 most recently, setting up a results season where investors are weighing...

Earlier this week, enGene Therapeutics reported interim Phase 2 LEGEND trial results for its bladder cancer gene therapy detalimogene voraplasmid, revealing a 54% complete response rate but weaker 12‑month durability than previously expected, alongside generally manageable side effects and low disease progression. The mixed efficacy profile has triggered analyst downgrades and shareholder-rights investigations, highlighting how a single data update can rapidly reshape perceptions of a...

If you are wondering whether Planet Labs PBC at around US$35.24 is priced attractively or already baking in big expectations, it helps to step back and look at how the stock has been behaving and what that might imply about value. The share price is around US$35.24, with a 4.7% decline over the last week, roughly flat at 0.2% over the past month, a 72.7% gain year to date, and a very large rise over the past year that is close to 9x, as well as very strong multi year returns. These moves...

NiSource (NYSE:NI) announced new and expanded partnerships with Amazon and Alphabet that are expected to support $1.4 billion in customer savings over 15 years. Alongside these partnerships, the company updated its long term adjusted EPS growth outlook to a range of 9% to 10% through 2033. For investors watching utilities, NiSource stands out with a current share price of $47.02 and a 5 year return of 115.2%. The stock has also returned 21.9% over the past year and 83.7% over 3 years,...

This article examines whether Primo Brands, trading at around US$22.24, currently represents value or risk by exploring what the share price might be implying. The stock has returned 9.1% over the last 7 days, 21.3% over the last 30 days and 37.4% year to date, while the 1 year return reflects a 29.8% decline and the 3 and 5 year returns are 69.8% and 48.4% respectively. Recent market interest in Primo Brands appears tied to broader investor attention on beverage companies listed in the US...

Guardant Health (GH) has just posted its FY 2025 numbers with Q4 revenue of US$281.3 million, a basic EPS loss of US$1.00 and net income loss of US$128.5 million, set against a trailing twelve month revenue base of US$982.0 million and a TTM EPS loss of US$3.32. Over recent quarters the company has seen revenue move from US$201.8 million in Q4 FY 2024 to US$281.3 million in Q4 FY 2025. Quarterly basic EPS losses have ranged between US$0.74 and US$1.00, and TTM net income losses have remained...

Encore Capital Group (NasdaqGS:ECPG) is asking shareholders to approve an amendment to its corporate charter. The change would exculpate company officers from personal liability for monetary damages tied to breaches of the duty of care. The proposal is scheduled for a vote at the upcoming annual shareholder meeting. Encore Capital Group operates in the consumer debt buying and collections space, where regulatory scrutiny, legal risk and reputational considerations tend to be front and...

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations. The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk. Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline...

Wondering whether Privia Health Group at around US$23.99 is offering fair value or a potential opportunity? This article breaks down what the current price may be telling you. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 7.2% gain over the last 30 days, and year to date returns of 2.3% after a 4.3% loss over the past year. Those mixed returns come against a backdrop of ongoing interest in healthcare services companies focused on physician enablement and...

Motorola Solutions (MSI) closed out FY 2025 with fourth quarter revenue of US$3.4 billion and basic EPS of US$3.90, supported by net income of US$649 million. Trailing 12 month figures show revenue of US$11.7 billion and basic EPS of US$12.93. Over the past year, revenue has moved from US$10.8 billion to US$11.7 billion and basic EPS has gone from US$9.45 to US$12.93, alongside trailing 12 month net income rising from US$1.6 billion to US$2.2 billion. This sets the backdrop for a profit story...

Wondering whether Verra Mobility stock is starting to look appealing at its current price, especially after a tough run? This article focuses squarely on what that price might really imply about value. The stock last closed at US$14.63 and has returned 0.5% over 30 days, yet year to date it is down 34.5% and the 1 year return is a 39.7% decline, which can change how investors think about both risk and opportunity. Recent coverage has focused on how the stock's weaker 1 year and 3 year...

Serve Robotics (SERV) has posted FY 2025 results that highlight a small but growing top line alongside sizable losses, with Q4 revenue at about US$0.9 million and a quarterly net loss of roughly US$34.3 million, or EPS of US$0.46 loss, while trailing 12 month revenue sits at roughly US$2.7 million against a net loss of about US$101.4 million and EPS of US$1.63 loss. Over recent quarters the company has seen revenue move from around US$0.18 million in Q4 FY 2024 to US$0.88 million in Q4 FY...

Akebia Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$53.54 million versus US$57.34 million a year earlier, with net loss of US$9.05 million replacing prior net income of US$6.11 million. A recent proposal to increase authorized capital stock to 525,000,000 shares, including 500,000,000 common shares, adds a potential dilution and financing angle to Akebia’s weaker quarterly performance. Next, we’ll examine how the shift to a quarterly loss alongside...

If you are wondering whether MetLife at around US$78.82 offers fair value or a margin of safety, this article explains what the current price might be indicating. The stock has returned 10.7% over the last 30 days, while the 1-year return is 3.8% and the 3-year return is 67.2%. These figures can influence how investors view both potential upside and risk. Recent coverage has highlighted MetLife's position as a major US insurance company. Investors have been focusing on how interest rate...

If you are wondering whether UGI is attractively priced or just a value trap, starting with the current share price and valuation checks can help frame the picture. UGI closed at US$32.32, with recent returns showing a 10.4% decline over 7 days, 12.7% over 30 days, 14.1% year to date, and 3.6% over 1 year. This is set against a 31.7% gain over 3 years and an 11.3% decline over 5 years. These mixed return figures sit alongside ongoing investor attention on UGI as a regulated utility and...

Airbnb (ABNB) has wrapped up FY 2025 with fourth quarter revenue of US$2.8b and basic EPS of US$0.56, capping a year where trailing twelve month revenue reached US$12.2b and EPS came in at US$4.10. Over the past few quarters, revenue has moved from US$2.5b in Q4 2024 to US$4.1b in Q3 2025 before landing at US$2.8b in Q4 2025. Over the same stretch, quarterly EPS shifted from US$0.74 to US$2.25 and then to US$0.56, giving investors a clearer view of how profitability tracks Airbnb’s seasonally...

QuantumScape (NasdaqGS:QS) has started operations at its Eagle Line pilot-scale solid-state battery production facility. The company has recorded its first billings from ecosystem partners, initiating its licensing and royalty revenue stream. These developments represent a shift from pure development work to initial commercialization and monetization of its battery technology. QuantumScape focuses on solid-state lithium-metal batteries aimed at electric vehicles and related applications, a...

Amphastar Pharmaceuticals (AMPH) closed out FY 2025 with fourth quarter revenue of US$183.1 million and basic EPS of US$0.53, compared with prior year Q4 revenue of US$186.5 million and EPS of US$0.79, as trailing net profit margin moved from 21.8% to 13.6% over the last 12 months. Over the past six reported quarters, revenue has remained within a relatively narrow range of roughly US$170 million to US$192 million per quarter, while EPS has ranged from US$0.37 to US$0.83, giving investors a...

Cellebrite DI's Cellebrite Government Cloud platform has received FedRAMP High Authorization, the top federal cloud security standard. The U.S. Department of Justice acted as the sponsoring agency for this authorization. The approval covers handling of highly sensitive unclassified data for federal agencies. Cellebrite DI (NasdaqGS:CLBT) now has its Cellebrite Government Cloud cleared at the FedRAMP High level, placing it among a relatively small group of vendors that meet the federal...

If you are wondering whether Fortive at around US$60.90 is still a fair deal or already pricing in the story, this breakdown will help you size up what you are really paying for the stock. Over the shorter term, Fortive has posted returns of 1.9% over the last week, 7.1% over the last month, 9.9% year to date and 16.3% over the past year, which raises questions about how much of the current valuation is already reflected in the recent share price. Recent attention on Fortive has centered on...